Cargando…

Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study

The PT-Cy was considered as one of the mainstay protocol for graft verus host disease (GVHD) prophylaxis. Recent study demonstrated that PT-Cy combined with other immunosuppressants could further reduce the incidence of GVHD and improve the GVHD and relapse free survival (GRFS). In this prospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Jie-ling, Gao, Wen-hui, Wang, Li-ning, Wan, Ming, Wang, Ling, Hu, Jiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012531/ https://www.ncbi.nlm.nih.gov/pubmed/33816524 http://dx.doi.org/10.3389/fmed.2021.630160

Ejemplares similares

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens
por: Yao, Janny M., et al.
Publicado: (2022)

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis
por: Gao, Wen-hui, et al.
Publicado: (2023)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
por: Dachy, F., et al.
Publicado: (2022)

Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors
por: Carnevale-Schianca, Fabrizio, et al.
Publicado: (2021)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT
por: Luo, Rongmu, et al.
Publicado: (2022)

Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies
por: Dou, Liping, et al.
Publicado: (2019)

The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety
por: Chen, Xiaoli, et al.
Publicado: (2021)

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia
por: Barkhordar, Maryam, et al.
Publicado: (2022)

Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
por: Szyska, Martin, et al.
Publicado: (2016)

Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation
por: Teshima, Takanori, et al.
Publicado: (2023)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia
por: Lazzari, Lorenzo, et al.
Publicado: (2022)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
por: Servais, Sophie, et al.
Publicado: (2015)

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
por: Wang, Yu, et al.
Publicado: (2019)

Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis
por: Zhou, Xiao, et al.
Publicado: (2022)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation
por: Duléry, Rémy, et al.
Publicado: (2021)

Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide
por: Marco, Daniel N., et al.
Publicado: (2022)

Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial
por: Zu, Yingling, et al.
Publicado: (2023)

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation
por: McGuirk, Joseph, et al.
Publicado: (2009)

Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD
por: Köhler, Natalie, et al.
Publicado: (2019)

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
por: Maurer, Katie, et al.
Publicado: (2023)

Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide
por: Espinoza-Gutarra, Manuel, et al.
Publicado: (2023)

Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
por: Shin, Ho Cheol, et al.
Publicado: (2012)

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
por: Hamadani, Mehdi, et al.
Publicado: (2020)

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies
por: Fang, Shu, et al.
Publicado: (2022)

Evaluation of clotrimazole prophylaxis on tacrolimus trough concentrations in kidney transplant recipients
por: Wings, Emily, et al.
Publicado: (2022)

Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis
por: Salas, Maria Queralt, et al.
Publicado: (2019)

Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation
por: Ullrich, Evelyn, et al.
Publicado: (2016)

Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD – A longitudinal study
por: Przybyla, Beata, et al.
Publicado: (2017)

Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
por: Hanaki, Ryo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sllmg4rpluvago5p6v80rqahi8